Developer docs
API playgroundTry for free, no card

Search company profiles

LSP BioVentures

Full company profile

uuid0002fws

Namestring
LSP BioVentures
Legal namestring
EQT Life Sciences (operating as Life Sciences Partners / LSP)
Websiteurl
lspvc.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

LSP BioVentures, operating commercially as EQT Life Sciences, is a European venture capital and growth-equity firm dedicated exclusively to the life sciences sector. Founded in 2001 as Life Sciences Partners (LSP) and rebranded under EQT Group in 2024, the firm manages approximately 3.5 billion EUR across 12 private funds organized around three strategies: Life Sciences Funds (LSP 1-7) for biotech drug development at all stages, Health Economic Funds for later-stage MedTech, digital health and diagnostics, and a specialized Dementia Fund for neurodegenerative disease. The firm invests 10-60M EUR per company and has backed over 150 private companies across therapeutics, medical devices, diagnostics and healthtech, with a current active portfolio of 65+ companies and 30+ investment professionals drawn from medical, scientific and industry backgrounds.

Revenue is generated through traditional fund-management economics: management fees on committed and invested capital across the 12 funds, supplemented by carried interest on successful exits such as Neuravi (acquired by Johnson & Johnson in 2017) and Amolyt Pharma (exited in 2024 at a 1bn+ valuation). Distribution of fund offerings occurs through qualified institutional investor LP channels, supported by a secure LP portal and direct outreach to entrepreneurs. Marketing and deal-sourcing channels include the annual BioCapital Europe conference, the THINQ content platform, a weekly newsletter, and direct referral/affiliate pathways.

Strategically, the firm is harvesting an active exit cycle (Tubulis to Gilead for up to USD 5.0 billion announced April 2026, Vivasure Medical to Haemonetics in January 2026) while extending its platform into radiopharmaceutical supply via a 2024 minority stake in PanTera alongside IBA and SCK CEN. Geographic reach spans Europe (Netherlands, Belgium, France, Ireland) and North America, with investments sourced globally. As part of EQT Group's Private Capital division, EQT Life Sciences operates with the institutional backing of one of Europe's largest alternative asset managers.

Short descriptiontext

LSP BioVentures, operating as EQT Life Sciences, is a European venture capital firm managing approximately 3.5 billion EUR across 12 life sciences funds, investing 10-60M EUR per company in therapeutics, MedTech, diagnostics, and healthtech companies globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funds, life sciences investing, biotech investment, medical device funding, healthcare private equity
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Venture Capital / Private Equity — Life Sciences
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeManaged Services
Description

EQT Life Sciences generates revenue through management fees and carried interest from its 12 private funds across three investment strategies (Life Sciences Funds LSP 1-7, Health Economic Funds, and Dementia Fund). Capital raised across funds totals approximately 3.5 billion EUR.

eqtgroup.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1LSP 1-7 (Life Sciences Funds)
Description

Biotech funds focused on drug development at all stages.

eqtgroup.com
+2 more records
Core offering1 text field

LSP BioVentures, operating as EQT Life Sciences, is a venture capital/private equity firm that invests in innovative life sciences companies developing therapeutics, medical devices, diagnostics, and healthtech. The firm deploys 10-60M EUR per company across three strategies — Life Sciences Funds (LSP 1-7), Health Economic Funds, and a Dementia Fund — while providing strategic, clinical, operational, financial, and commercial guidance to portfolio companies. It has raised approximately 3.5 billion EUR across 12 private funds and invested in over 150 companies globally over a 30-year track record.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Neuravi acquired by Johnson & Johnson in 2017, just two years after initial investment
+1 more record
Product overview1 text field

EQT Life Sciences (formerly LSP BioVentures/Life Sciences Partners) is one of Europe's largest life sciences investors offering a family of specialized investment funds. The firm operates three core investment strategies: Life Sciences Funds (LSP 1-7) focused on biotech and drug development at all stages, Health Economic Funds targeting later-stage MedTech, Digital Health and Diagnostics companies, and a specialized Dementia Fund for neurodegenerative disease investments. The fund family collectively spans over 30 years of history with approximately 3.5 billion euros raised across 12 private funds. Investment advisory services include capital deployment as well as strategic, clinical, operational, financial, and commercial guidance for portfolio companies.

Product and service3 records
1Life Sciences Funds (LSP 1-7)
CategoryInvestment Fund
Description

Biotech investment funds focused on drug development at all stages, deploying capital of 10-60M EUR per company into innovative therapeutics developers globally. For institutional limited partners and life sciences entrepreneurs.

2Health Economic Funds (LSP HEF 1-2 / EQT HE 3)
3Dementia Fund
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Ion Beam Applications (IBA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

IBA is a Belgian company and co-founder of PanTera, the joint venture producing Ac-225 radioisotope for cancer treatment. IBA and SCK CEN established PanTera in 2022, with EQT Life Sciences joining as an investor in 2024.

eqtgroup.com
2SCK CEN (Belgian Nuclear Research Centre)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

SCK CEN is the Belgian Nuclear Research Centre and co-founder of PanTera, the joint venture producing Ac-225 radioisotope for cancer treatment. SCK CEN brings nuclear research expertise to the partnership.

eqtgroup.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Versant Ventures is a healthcare-focused venture capital firm with operations in the US, Canada, and Europe. Comparable to EQT Life Sciences given transatlantic life sciences focus, multiple specialized strategies, and similar AUM scale.

TypeDirect peer
Description

ARCH Venture Partners is a US-based venture firm focused on founding and building biotech companies. Comparable as a long-tenured life sciences specialist with large fund vintages, though US-focused rather than European.

TypeDirect peer
Description

Novo Ventures is the venture investment arm of Novo Holdings, a major global life sciences investor. Directly comparable as a long-duration life sciences investor with multi-billion AUM and focus on therapeutics development, with even larger scale than EQT Life Sciences.

TypeDirect peer
Description

Sofinnova is a Paris-headquartered European life sciences VC with multiple specialized strategies including Crossover, Industrial Biotech, and MedTech. Highly comparable as a fellow European specialist life sciences investor with similar AUM scale and stage focus.

TypeDirect peer
Description

Abingworth is a transatlantic life sciences investment firm with venture and clinical co-development strategies. Comparable to EQT Life Sciences given its specialized focus on therapeutics and medical devices with similar fund sizes and stage flexibility.

TypeBroad incumbent
Description

OrbiMed is a global healthcare-dedicated investment firm with public and private strategies across stages. Comparable as a large life sciences investor with multi-strategy approach, though significantly larger AUM and US-headquartered.

TypeDirect peer
Description

Forbion is a leading European life sciences venture capital firm managing multiple funds focused on biotech and MedTech investments. Directly comparable to EQT Life Sciences given similar European footprint, fund sizes in the hundreds of millions of euros, and focus on therapeutics and medical device companies.

TypeBroad incumbent
Description

GIMV is a Belgian-listed private equity and venture capital firm with a meaningful health and care investment vertical. Comparable as a European PE firm with healthcare focus, though broader than EQT Life Sciences' pure-play life sciences strategy.

TypeDirect peer
Description

Atlas Venture is an early-stage life sciences VC firm focused on building biotech companies from inception. Comparable to EQT Life Sciences' LSP funds in stage focus and therapeutic orientation, though typically earlier-stage.

TypeDirect peer
Description

Kurma Partners is a Paris-based European healthcare and life sciences VC firm. Directly comparable as a European specialist life sciences investor with similar stage focus on therapeutics and MedTech.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment29 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LSP BioVentures

Venture Capital / Private Equity — Life Scienceslspvc.com

LSP BioVentures, operating as EQT Life Sciences, is a European venture capital firm managing approximately 3.5 billion EUR across 12 life sciences funds, investing 10-60M EUR per company in therapeutics, MedTech, diagnostics, and healthtech companies globally.

What LSP BioVentures does

LSP BioVentures, operating commercially as EQT Life Sciences, is a European venture capital and growth-equity firm dedicated exclusively to the life sciences sector. Founded in 2001 as Life Sciences Partners (LSP) and rebranded under EQT Group in 2024, the firm manages approximately 3.5 billion EUR across 12 private funds organized around three strategies: Life Sciences Funds (LSP 1-7) for biotech drug development at all stages, Health Economic Funds for later-stage MedTech, digital health and diagnostics, and a specialized Dementia Fund for neurodegenerative disease. The firm invests 10-60M EUR per company and has backed over 150 private companies across therapeutics, medical devices, diagnostics and healthtech, with a current active portfolio of 65+ companies and 30+ investment professionals drawn from medical, scientific and industry backgrounds.

Revenue is generated through traditional fund-management economics: management fees on committed and invested capital across the 12 funds, supplemented by carried interest on successful exits such as Neuravi (acquired by Johnson & Johnson in 2017) and Amolyt Pharma (exited in 2024 at a 1bn+ valuation). Distribution of fund offerings occurs through qualified institutional investor LP channels, supported by a secure LP portal and direct outreach to entrepreneurs. Marketing and deal-sourcing channels include the annual BioCapital Europe conference, the THINQ content platform, a weekly newsletter, and direct referral/affiliate pathways.

Strategically, the firm is harvesting an active exit cycle (Tubulis to Gilead for up to USD 5.0 billion announced April 2026, Vivasure Medical to Haemonetics in January 2026) while extending its platform into radiopharmaceutical supply via a 2024 minority stake in PanTera alongside IBA and SCK CEN. Geographic reach spans Europe (Netherlands, Belgium, France, Ireland) and North America, with investments sourced globally. As part of EQT Group's Private Capital division, EQT Life Sciences operates with the institutional backing of one of Europe's largest alternative asset managers.

LSP BioVentures firmographics

Firmographics
Name
LSP BioVentures
Legal name
EQT Life Sciences (operating as Life Sciences Partners / LSP)
Website
https://lspvc.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
LSP BioVentures, operating as EQT Life Sciences, is a European venture capital firm managing approximately 3.5 billion EUR across 12 life sciences funds, investing 10-60M EUR per company in therapeutics, MedTech, diagnostics, and healthtech companies globally.
Ownership category
akta.pro rank

Where LSP BioVentures is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

LSP BioVentures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Fund Management: EQT Life Sciences generates revenue through management fees and carried interest from its 12 private funds across three investment strategies (Life Sciences Funds LSP 1-7, Health Economic Funds, and Dementia Fund). Capital raised across funds totals approximately 3.5 billion EUR.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

LSP BioVentures product offering

Product offering

Core offering

LSP BioVentures, operating as EQT Life Sciences, is a venture capital/private equity firm that invests in innovative life sciences companies developing therapeutics, medical devices, diagnostics, and healthtech. The firm deploys 10-60M EUR per company across three strategies — Life Sciences Funds (LSP 1-7), Health Economic Funds, and a Dementia Fund — while providing strategic, clinical, operational, financial, and commercial guidance to portfolio companies. It has raised approximately 3.5 billion EUR across 12 private funds and invested in over 150 companies globally over a 30-year track record.

Product overview

EQT Life Sciences (formerly LSP BioVentures/Life Sciences Partners) is one of Europe's largest life sciences investors offering a family of specialized investment funds. The firm operates three core investment strategies: Life Sciences Funds (LSP 1-7) focused on biotech and drug development at all stages, Health Economic Funds targeting later-stage MedTech, Digital Health and Diagnostics companies, and a specialized Dementia Fund for neurodegenerative disease investments. The fund family collectively spans over 30 years of history with approximately 3.5 billion euros raised across 12 private funds. Investment advisory services include capital deployment as well as strategic, clinical, operational, financial, and commercial guidance for portfolio companies.

Differentiator

Problem solved

Functional benefit

Brands

  • LSP 1-7 (Life Sciences Funds): Biotech funds focused on drug development at all stages.
  • Health Economic Funds (LSP HEF 1-2, EQT HE 3)
  • Dementia Fund (LSP Dementia)

Products and services

  • Life Sciences Funds (LSP 1-7) Biotech investment funds focused on drug development at all stages, deploying capital of 10-60M EUR per company into innovative therapeutics developers globally. For institutional limited partners and life sciences entrepreneurs.
  • Health Economic Funds (LSP HEF 1-2 / EQT HE 3)
  • Dementia Fund

Quantifiable outcome

  • Neuravi acquired by Johnson & Johnson in 2017, just two years after initial investment
  • +1 more outcomes

Companies that use LSP BioVentures

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

LSP BioVentures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LSP BioVentures partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Ion Beam Applications (IBA)coreStrategic or Co-development Partner · 1 January 2022IBA is a Belgian company and co-founder of PanTera, the joint venture producing Ac-225 radioisotope for cancer treatment. IBA and SCK CEN established PanTera in 2022, with EQT Life Sciences joining as an investor in 2024.
  • SCK CEN (Belgian Nuclear Research Centre)coreStrategic or Co-development Partner · 1 January 2022SCK CEN is the Belgian Nuclear Research Centre and co-founder of PanTera, the joint venture producing Ac-225 radioisotope for cancer treatment. SCK CEN brings nuclear research expertise to the partnership.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

LSP BioVentures competitors and assessment

Company assessment

Direct peers

  • Versant Ventures: Versant Ventures is a healthcare-focused venture capital firm with operations in the US, Canada, and Europe. Comparable to EQT Life Sciences given transatlantic life sciences focus, multiple specialized strategies, and similar AUM scale.
  • ARCH Venture Partners: ARCH Venture Partners is a US-based venture firm focused on founding and building biotech companies. Comparable as a long-tenured life sciences specialist with large fund vintages, though US-focused rather than European.
  • Novo Holdings (Novo Ventures): Novo Ventures is the venture investment arm of Novo Holdings, a major global life sciences investor. Directly comparable as a long-duration life sciences investor with multi-billion AUM and focus on therapeutics development, with even larger scale than EQT Life Sciences.
  • Sofinnova Partners: Sofinnova is a Paris-headquartered European life sciences VC with multiple specialized strategies including Crossover, Industrial Biotech, and MedTech. Highly comparable as a fellow European specialist life sciences investor with similar AUM scale and stage focus.
  • Abingworth: Abingworth is a transatlantic life sciences investment firm with venture and clinical co-development strategies. Comparable to EQT Life Sciences given its specialized focus on therapeutics and medical devices with similar fund sizes and stage flexibility.
  • Forbion: Forbion is a leading European life sciences venture capital firm managing multiple funds focused on biotech and MedTech investments. Directly comparable to EQT Life Sciences given similar European footprint, fund sizes in the hundreds of millions of euros, and focus on therapeutics and medical device companies.
  • Atlas Venture: Atlas Venture is an early-stage life sciences VC firm focused on building biotech companies from inception. Comparable to EQT Life Sciences' LSP funds in stage focus and therapeutic orientation, though typically earlier-stage.
  • Kurma Partners: Kurma Partners is a Paris-based European healthcare and life sciences VC firm. Directly comparable as a European specialist life sciences investor with similar stage focus on therapeutics and MedTech.

Broad incumbents

  • OrbiMed Advisors: OrbiMed is a global healthcare-dedicated investment firm with public and private strategies across stages. Comparable as a large life sciences investor with multi-strategy approach, though significantly larger AUM and US-headquartered.
  • GIMV: GIMV is a Belgian-listed private equity and venture capital firm with a meaningful health and care investment vertical. Comparable as a European PE firm with healthcare focus, though broader than EQT Life Sciences' pure-play life sciences strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

LSP BioVentures social profiles

Digital presence

LSP BioVentures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LSP BioVentures leadership team

Management profile

Number of profiles

Profiles4 records

LSP BioVentures subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

LSP BioVentures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LSP BioVentures M&A and investment

M&A and investment

M&A

Investments29 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LSP BioVentures

What does LSP BioVentures do?

LSP BioVentures, operating as EQT Life Sciences, is a venture capital/private equity firm that invests in innovative life sciences companies developing therapeutics, medical devices, diagnostics, and healthtech. The firm deploys 10-60M EUR per company across three strategies — Life Sciences Funds (LSP 1-7), Health Economic Funds, and a Dementia Fund — while providing strategic, clinical, operational, financial, and commercial guidance to portfolio companies. It has raised approximately 3.5 billion EUR across 12 private funds and invested in over 150 companies globally over a 30-year track record.

Is LSP BioVentures a public or private company?

LSP BioVentures is a private company. It is classified as corporate owned and is currently operating.

When was LSP BioVentures founded?

LSP BioVentures was founded in 2001. It employs 11 to 50 people.

Where is LSP BioVentures based?

LSP BioVentures is headquartered in Amsterdam, Netherlands, in the Europe region.

How does LSP BioVentures make money?

One revenue line is on record: fund Management.

Who are LSP BioVentures's main competitors?

Direct peers on record are Versant Ventures, ARCH Venture Partners, Novo Holdings (Novo Ventures), Sofinnova Partners, Abingworth, Forbion, Atlas Venture and Kurma Partners. Broad incumbents are OrbiMed Advisors and GIMV.

Does LSP BioVentures have an API?

No public API is recorded for LSP BioVentures.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireOculis Announces US Public Listing on NASDAQOculis Holding AG listed on Nasdaq under ticker OCS after closing its business combination with European Biotech Acquisition Corp. The deal created a company with a pro-forma enterprise value of about $220 million and a cash balance exceeding $117 million, backed by a $91 million PIPE led by LSP 7. Near-term milestones include results from the DIAMOND study for OCS-01, a topical eye drop for diabetic macular edema.MedicaldesignandoutsourcingOneProjects raises $17M to advance 4D cardiac imagingIrish-German cardiac imaging startup OneProjects announced $8 million in Series A2 funding and two grants totaling $9 million, led by imec.xpand with participation from the EIC Fund and existing investors LSP and Atlantic Bridge Ventures. The company will use the funds for product development, clinical trials and FDA clearance of Verafeye, a catheter-based 4D cardiac imaging platform.European BiotechnologyVisus Therapeutics cashes in €20m from LSPOphthalmic therapies specialist Visus Therapeutics closed a $20 million preferred stock financing led by LSP's LSP 6 fund, with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation and other inside investors. The funds will advance Brimochol, a once-daily presbyopia eye drop combining carbachol and brimonidine, studied in over 200 patients across six trials. Topline Phase II data are expected in the second half of 2021.FinSMEsVisus Therapeutics Raises $20M in FundingVisus Therapeutics, Inc. raised $20 million in funding to advance its clinical and commercial efforts for its lead asset BRIMOCHOL™, an investigational drug targeting presbyopia. The funding round was led by LSP and included participation from Johnson & Johnson Innovation - JJDC, Inc. and Sage Partners, among others, with plans to use the funds for further drug development and clinical studies.Venture Capital Access OnlineVisus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage PartnersVisus Therapeutics announced that it has closed $20 million in preferred stock financing led by LSP, with participation from Sage Partners, aimed at supporting the clinical and commercial efforts for its lead asset, BRIMOCHOL™, and further research and development. This financing comes ahead of the anticipated Phase 2 topline readout of BRIMOCHOL, an investigational eye drop for treating presbyopia, with plans to soon initiate pivotal Phase 3 studies. The investment is expected to enhance the company's global investor base and aid in addressing unmet patient needs.BioSpaceVisus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage PartnersVisus Therapeutics raised $20 million in additional financing led by LSP, with participation from Sage Partners. The proceeds will support clinical and commercial efforts for its presbyopia lead asset BRIMOCHOL and new R&D activities. The company will host its first Capital Markets Day in New York City on August 31, 2021.VentureBeatVisus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage PartnersVisus Therapeutics closed a $20 million preferred stock financing round led by LSP, with participation from Sage Partners and Johnson & Johnson Innovation - JJDC, Inc. The proceeds will support clinical and commercial efforts for its lead asset BRIMOCHOL™, an investigational treatment for presbyopia, as well as new research and development activities. In conjunction with the financing, John de Koning of LSP joined the company's Board of Directors.GlobeNewswireInnovative Molecules raises €20 million Series A equity financing roundInnovative Molecules GmbH has closed a €20 million Series A equity financing round led by LSP to advance its preclinical drug candidate IM-250 into Phase II clinical trials. The funding will support the development of IM-250, a potent inhibitor targeting Herpes Simplex Virus replication and reservoirs.European BiotechnologyLSP leads €11m Series A round in OneProjectLSP led an €11m Series A round for OneProject, with Atlantic Bridge University Fund as co-investor. The funding will advance VERAFEYE, a medical imaging system for cardiac arrhythmia treatment, including clinical trials and US commercialisation. The system aims to improve catheter ablation efficacy for atrial fibrillation.Silicon RepublicIrish-German medtech firm OneProjects bags €11m in Series AOneProjects, an Irish-German medtech firm, raised €11m in Series A funding led by LSP to develop its Verafeye technology for atrial fibrillation treatment. The funds will advance product development, clinical trials, and US commercialisation. The company aims to have its products in the market in the not too distant future.